Physician profile
Codie Bingham
NPI 1265080154
$6,430.99
in general payments reported to CMS, 2019-2025
27 companies · $3,106 in 2025
The $3,106 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $226 · 2022: $803 · 2023: $735 · 2024: $1,561 · 2025: $3,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,229 · Travel and Lodging: $1,080 · Consulting Fee: $750 · Education: $343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,229.11 |
| Travel and Lodging | $1,079.59 |
| Consulting Fee | $750.00 |
| Education | $343.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,427.81 | 2022-2025 | Inspire |
| Actelion Pharmaceuticals US, INC. | $1,127.41 | 2022-2025 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $779.70 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $669.18 | 2021-2025 | Breztri, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $320.59 | 2021-2025 | Nucala, Trelegy Ellipta |
| United Therapeutics Corporation | $288.01 | 2022-2025 | Tyvaso |
| Jazz Pharmaceuticals INC. | $222.64 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $221.61 | 2024-2025 | Dupixent |
| Harmony Biosciences LLC | $211.10 | 2023-2025 | Wakix |
| Merck Sharp & Dohme LLC | $155.17 | 2024-2025 | Winrevair |
| Axsome Therapeutics, INC. | $137.61 | 2024-2025 | Sunosi |
| Zoll Respicardia, INC. | $125.00 | 2024 | Remede System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.13 | 2024-2025 | Ofev, Jascayd |
| Takeda Pharmaceuticals U.S.A., INC. | $115.77 | 2024-2025 | Glassia |
| Baxter Healthcare | $86.18 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $81.99 | 2022 | |
| Genzyme Corporation | $73.88 | 2023 | |
| Grifols USA, LLC | $62.43 | 2024-2025 | Prolastin-C Liquid |
| Verona Pharma, INC. | $56.70 | 2025 | Ohtuvayre |
| Inogen, INC. | $26.88 | 2022-2024 | |
| Avadel Cns Pharmaceuticals, LLC | $24.27 | 2025 | Lumryz |
| Pulmonx Corporation | $20.89 | 2024 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Insmed, INC. | $16.92 | 2025 | Brinsupri, Arikayce |
| Boston Scientific Corporation | $16.02 | 2025 | General - Pain Management |
| Philips North America LLC | $14.52 | 2024 | (8874) Incourage |
| Mylan Specialty L.P. | $14.43 | 2023 | Yupelri |
| Janssen Pharmaceuticals, INC | $11.15 | 2024 | Uptravi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Codie Bingham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.